AstraZeneca has granted Actavis a head start in the race to cash in on the loss of US market exclusivity of Crestor (rosuvastatin calcium), its top-selling drug, in 2016. The latter had been attempting to bypass the usual process of generic market entry by threatening to launch a similar, but not substitutable, version of rosuvastatin, forcing AstraZeneca to argue patent infringement in the courts to defend its top-selling product.
AstraZeneca gives Actavis generic Crestor head start
AstraZeneca has granted Actavis a head start in the race to cash in on the loss of US market exclusivity of Crestor (rosuvastatin calcium), its top-selling drug, in 2016. The latter had been attempting to bypass the usual process of generic market entry by threatening to launch a similar, but not substitutable, version of rosuvastatin, forcing AstraZeneca to argue patent infringement in the courts to defend its top-selling product.
More from Archive
• By
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
• By
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
• By
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
• By
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
More from Scrip
• By
DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.
• By
Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.
• By
MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.